SNU-1 Xenograft Model Service for Gastric Cancer

The SNU-1 xenograft model offers a robust preclinical platform for evaluating therapeutic candidates against gastric adenocarcinoma, recapitulating the aggressive growth patterns and molecular signatures characteristic of this malignancy. Alfa Cytology delivers comprehensive SNU-1 xenograft model services---from cell authentication and tumor engraftment to endpoint analysis---empowering your preclinical pipeline with reliable, reproducible data generated under stringent quality standards.

Overview of SNU-1 Xenograft Model for Gastric Cancer

The SNU-1 cell line was established in 1984 from a poorly differentiated primary gastric carcinoma resected from a 44-year-old Asian male patient prior to cytotoxic therapy. As a near-diploid cell line with a modal chromosome number of 47, SNU-1 exhibits a hyperdiploid karyotype featuring the stable translocation t(1;4)(q24;q33) and double minute chromosomes in approximately 28% of cells. The cells grow as floating multicellular aggregates with a population doubling time of approximately 26 hours, and display epithelial morphology with expression of carcinoembryonic antigen (CEA), TAG-72, and cytokeratins---markers consistent with gastric adenocarcinoma origin.

In xenograft applications, SNU-1 reliably forms tumors in immunodeficient hosts such as NSG mice, providing a physiologically relevant system for studying gastric cancer biology, tumor-stroma interactions, and therapeutic response. The model retains key molecular characteristics of the original tumor, including c-myc and c-erb-B2 expression, microsatellite instability (MSI), and hMLH1 deficiency, making it particularly valuable for investigating DNA mismatch repair defects, TGF-beta resistance, and the efficacy of targeted agents and combination regimens in preclinical settings.

Figure 1. Evaluation of the CI. The CI values of 5-FU and escitalopram oxalate on the SNU-1 cells for (A) 24 and (B) 48 h. (Chen, Vincent Chin-Hung, et al., 2022)

Cell Line Information: SNU-1

The SNU-1 cell line represents a well-characterized model of human gastric adenocarcinoma with the following detailed specifications:

Our Services

Alfa Cytology leverages decades of collective expertise in oncology model development to provide end-to-end SNU-1 xenograft services tailored to your preclinical objectives. From pilot feasibility studies through full-scale efficacy assessments, our integrated platform combines rigorous cell line authentication, optimized engraftment protocols, and comprehensive endpoint analyses---including tumor growth kinetics, biomarker profiling, and histopathological evaluation---to accelerate your therapeutic development timeline with confidence.

Workflow of SNU-1 Xenograft Model Construction

The construction of the SNU-1 xenograft model follows a standardized, quality-controlled workflow designed to ensure high engraftment rates, consistent tumor growth, and reliable therapeutic readouts. Each stage is optimized to preserve the biological fidelity of the SNU-1 cell line while accommodating client-specific study requirements.

1. Step 1: Cell Authentication and Preparation --- SNU-1 cells are revived from authenticated master stocks and expanded under defined culture conditions. Prior to inoculation, cells undergo quality verification including morphology assessment, growth curve analysis, and mycoplasma testing to confirm identity and viability.
2. Step 2: Recipient Mouse Selection and Conditioning --- Immunodeficient NSG or nude mice are selected based on study design and conditioned under pathogen-free housing. Animals are acclimatized for a minimum period and randomized according to body weight and health status prior to tumor cell inoculation.
3. Step 3: Tumor Cell Inoculation --- SNU-1 cells are harvested at logarithmic growth phase, washed, and resuspended in a serum-free medium mixed with Matrigel or PBS at optimized concentrations. The cell suspension is inoculated subcutaneously into the flank or orthotopically into the gastric wall, depending on the study objectives.
4. Step 4: Tumor Monitoring and Randomization --- Following inoculation, animals are monitored daily for general health and twice weekly for tumor appearance. Palpable tumors are measured using digital calipers, and mice are randomized into treatment cohorts once tumors reach a predetermined volume (typically 100-150 mm^3).
5. Step 5: Treatment Administration and Dosing --- Test compounds are administered according to predefined schedules (oral gavage, intraperitoneal, intravenous, or intratumoral). Vehicle control and positive control groups are included to ensure assay sensitivity and reproducibility.
6. Step 6: Endpoint Analysis and Data Collection --- At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E, IHC), biomarker profiling (Western blot, qPCR, flow cytometry), and pharmacokinetic studies. Comprehensive data packages are compiled for client review.

Figure 2: Schematic workflow illustrating the derivation and construction of the SNU-1 Xenograft Model at Alfa Cytology.

Case Study-SNU-1 Xenograft Model Development

In a representative preclinical engagement, the SNU-1 xenograft model was successfully established in immunodeficient mice with consistent tumor take rates and exponential growth kinetics characteristic of poorly differentiated gastric adenocarcinoma. Treatment arms evaluating candidate therapeutic agents demonstrated dose-dependent tumor growth inhibition relative to vehicle controls, with corresponding changes in tumor proliferation markers and apoptotic indices observed at endpoint histopathological analysis. This case illustrates the utility of the SNU-1 model in generating actionable efficacy data for gastric cancer drug development programs.

Why Choose Alfa Cytology?

Alfa Cytology stands apart as a trusted preclinical partner through our unwavering commitment to scientific rigor, operational transparency, and client-centric service delivery.

• Authenticated cell lines with comprehensive quality control and documentation ensure biological fidelity across every study.
• Customizable study designs accommodate diverse therapeutic modalities including small molecules, biologics, oncolytic viruses, and combination regimens.
• Rapid project initiation with dedicated study management and real-time data access through our secure client portal.
• Integrated endpoint capabilities spanning tumor growth analysis, biomarker quantification, histopathology, and pharmacokinetic sampling.
• Competitive timelines and flexible milestone-based billing aligned with preclinical program requirements.

Contact Us

Ready to advance your gastric cancer therapeutic program with the SNU-1 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our SNU-1 Xenograft Model services.

For research use only. Not intended for any clinical use.